Dr. Robert Gerszten Receives Agilent Thought Leader Award
News Dec 20, 2012
Agilent Technologies Inc. has announced that Dr. Robert Gerszten, a recognized leader in cardiovascular research and biomarker discovery, has received an Agilent Thought Leader Award.
Dr. Gerszten is the director of clinical and translational research at Massachusetts General Hospital's Institute for Heart, Vascular and Stroke Care. The award will provide his laboratory with funding for personnel.
Agilent will also provide technical and scientific expertise in metabolomics, automation and integrated biology in support of Dr. Gerszten's metabolite profiling study of well-phenotyped human populations, including his work with the Framingham Heart Study.
"Our goal is to identify new metabolites and proteins that mark disease activity, signal disease progression, and ultimately provide targets for therapeutic intervention," said Dr. Gerszten.
Dr. Gerszten continued, "We are grateful that Agilent supports our research and is helping us in our quest to advance translational cardiology."
"Agilent is proud to support Dr. Gerszten's research in this pivotal project and further advance progress in the important field of cardiometabolic diseases," said Agilent CTO Darlene Solomon, the executive sponsor of the award.
Solomon continued, "By providing support and cutting-edge technologies to leading translational researchers like Dr. Gerszten, we aim to facilitate innovative research and to progress the fields of metabolomics and integrated biology toward improved patient outcomes."
The Agilent Thought Leader Award program promotes fundamental advances by contributing philanthropic financial support, products and expertise to the research of thought leaders in the life sciences and chemical analysis.
New Biosensor is Simple Solution for Metabolite DetectionNews
A novel concept for a metabolite biosensor which combines an electron transporting polymer with a redox enzyme could be adapted to detect any metabolite of interest.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE